The Preoperative Lymphocyte to Monocyte Ratio Predicts Clinical Outcome In Resected Patients With T2-4N0-3M0 Siewert Type II/III Adenocarcinoma Of The Esophagogastric Junction

Chen Ke (chenkeahmu@163.com)  
First Affiliated Hospital of Anhui Medical University

Jiawei Zhang  
First Affiliated Hospital of Anhui Medical University

Bo Chen  
First Affiliated Hospital of Anhui Medical University

Maoming Xiong  
First Affiliated Hospital of Anhui Medical University

Aman Xu  
First Affiliated Hospital of Anhui Medical University

Research article

Keywords: lymphocyte to monocyte ratio, adenocarcinoma of the esophagogastric junction, Biomarkers, Survival,

DOI: https://doi.org/10.21203/rs.3.rs-154104/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background Inflammation has a critical role in the pathogenesis and progression of cancer. The lymphocyte to monocyte ratio (LMR) could be a new biomarker in various tumors.

Aims We analyzed the LMR with clinicopathological parameters and outcome in resected patients with T_{2-4}N_{0-3}M_{0} Siewert type II/III of advanced adenocarcinoma of the esophagogastric junction (AEG).

Methods A total of five hundred and seventy-one patients with Siewert type II/III of AEG between Jan 2006 and Jun 2012 were included in this retrospective study. Kaplan-Meier curves were used to calculate the cancer-specific survival (CSS). Univariate and multivariate Cox-regression analyses were performed to evaluate the prognostic factors.

Results We set 3.64 as the cut-off level based on the receiver operating characteristic curve. The preoperative absolute lymphocyte count tended to decrease in ‘LMR ≤ 3.64’ group, and the preoperative absolute monocyte count tended to decrease in ‘LMR > 3.64’ group. The decreased preoperative LMR was significantly associated with decreased CSS in univariate (HR: 2.311, 95%CI: 1.639-3.254, P=0.008) and multivariate analysis (HR: 1.642, 95%CI: 1.242-2.171, P=0.027). According to the treatment regimen (surgery alone versus surgery and adjuvant chemotherapy), no significant difference in the 5-year CSS was identified in ‘high-risk’ group (LMR ≤ 3.64) (HR: 1.121, 95%CI: 0.733-1.725, P=0.605).

Conclusions The LMR might be an independent prognostic marker for CSS in resected patients with T_{2-4}N_{0-3}M_{0} Siewert type II/III of advanced AEG. When the ‘high-risk’ patients with LMR ≤ 3.64 were analyzed, no benefit of adjuvant 5-FU-based chemotherapy could be found.

Introduction

In the recent decades the incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increased in the worldwide[1]. Especially in China, due to the lack of routine screening, AEG is often diagnosed at the advanced staged (T2+) with or without lymph nodes metastasis and hematogenous dissemination[2], so the mortality caused by AEG is higher than the other gastrointestinal tumors. According to the distance between the tumor center and the anatomic esophagogastric junction (EGJ), AEG was divided into three subgroups by Siewert’s classification[3]. Type I (adenocarcinoma of the distal esophagus with the tumor center located within 1 cm to 5 cm above the EGJ) is the most prevalent type in Western countries. It is often treated as distal esophageal cancer[4]. Type II (true adenocarcinoma of the cardiac with the tumor center located within 1 cm above and 2 cm below the EGJ) and the type III (subcardial adenocarcinoma that infiltrates the esophagogastric junction with the tumor center located within 2 cm and 5 cm below the EGJ) are more common than type I and are mostly treated as proximal gastric cancer in China. Because of the different characteristics, the surgical technique and treatment strategies are different in three subgroups. Although the great development of radical surgery and adjuvant chemotherapy, long time survival rates for non-metastatic AEG range from 18 to 50 percent after
curative surgery\textsuperscript{[5]}. In some trials, chemotherapy based on 5-fluorouracil with oxaliplatin or docetaxel may improve patient outcomes\textsuperscript{[6]}. However, there are still a large number of advanced AEG patients after receiving radical surgery can not benefit from 5-fluorouracil-based chemotherapy\textsuperscript{[7]}. The high mortality is primarily related to complications of tumor dissemination. As we all know, lots of studies evaluated the association of various biomarkers with clinical outcome in gastrointestinal tumor. Owing of high costs, lack of standardization, and limited availability, the biomarkers still can not come into routine clinical practice\textsuperscript{[8,9]}. Some evidence revealed that tumor-associated inflammation could play an important role in cancer progression and prognosis. Previous studies have suggested that the preoperative peripheral blood cells can reflect the systemic inflammation, such as lymphocyte to monocyte ratio(LMR). Some studies show that survival benefit is associated with an increased pretreatment LMR\textsuperscript{[10,11]}. The LMR might be a good reflection of host’s immune response and tumor burden. However, the prognostic value of the LMR in advanced AEG has not been reported. The aim of this study was to investigate the clinical significance and the prognostic value of the preoperative LMR for resected patients with $T_2-4N_0-3M_0$ Siewert type II/III of advanced AEG.

**Materials And Methods**

**Patients and specimens**

We conducted this study on consecutive patients with Siewert type II and III of AEG. A total of 708 patients with histologically confirmed AEG were included in this study. All patients were treated at the first ward of gastrointestinal surgery in The First Affiliated Hospital of Anhui Medical University from Jan 2006 to Jun 2012. In our hospital, type II of AEG were treated at thoracic surgery as the distal esophageal cancer, type III and IV were treated at gastrointestinal surgery. All the patients were in relatively fine overall conditions without severe dysfunction of important organs or systematic unfit like dyscrasia, rheumatic disease or hypohepatia. Patients undergoing multivisceral resection or having other gastroenteric diseases were excluded from our study. To avoid possible effects of such treatments on preoperative laboratory profiles those who had received neoadjuvant chemotherapy or received a blood product transfusion within one month before resection were also excluded. They also had not received any radiotherapy or interventional therapy before. Besides, patients were confirmed without severe mental disorders.

All enrolled patients underwent radical surgery. For type II adenocarcinomas invading the distal of esophagus, transhiatal total gastrectomy or proximal gastrectomy combined with mediastinal lymphadenectomy was preferred. Thoracoabdominal incision might be performed for subtotal esophagectomy to guarantee curability, if the frozen section of proximal esophageal cutting edge was positive. For type III AEG, transabdominal TG was performed in our department of gastrointestinal surgery. D2 lymphadenectomy was routinely performed. The inferior mediastinal or extended lymph node dissection was performed for patients with esophageal involvement. Intraoperative frozen section was a routine procedure aiming to secure the tumor cells free from the resection margins. All operations were
conducted by the same group of surgeons who routinely operated on more than 50 cases per year and who had surgical practice of 5 or more consecutive years.

After radical surgery, 453 patients received 4–6 cycles of first-line adjuvant combination chemotherapy. 231 patients received 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX), and 222 patients received a prodrug of 5-fluorouracil (capecitabine; CapeOX). The flow chart of study population was shown in Fig. 1.

**Evaluation And Staging**

Clinical stage was assessed according to computed tomography (CT) and ultrasound endoscope examinations. In our department, preoperative abdominal CT and ultrasound endoscope are examined routinely. After surgery, the tumor were staged according to the tumor-node-metastasis (TNM) criteria from the 7th edition of the International Union Against Cancer’s classification.

**Laboratory Date**

As part of pretreatment evaluation, all patients’ peripheral blood samples were collected into tubes containing dipotassium ethylenedinitrotetra-acetic acid (EDTA) at 3 days before surgery and all measurements were performed within 30 min after blood collection. The peripheral LMR was calculated as the ratio of absolute counts between peripheral lymphocytes and monocytes. Analysis of the white blood cell count was performed in the routine laboratory of our hospital (Sysmex XE-2100 Hematology Analyzer).

**Follow-up**

Enrolled patients were prospectively followed-up until Jun 2017. Follow-up was performed in regular intervals (every 3 months for the first 2 years after treatment, every 6 months intervals in 3–5 years and every 12 months intervals after 5 years). Follow-up evaluations included clinical check-up, laboratory including complete blood count (CBC), liver function test, and radiological assessment (liver scan and chest X-ray every 6 months). All of the clinical features were retrospectively obtained from the patients’ history. Follow-up data were available.

**Statistical analysis**

As the current study described the prognosis of patients with AEG II/III, therefore, a cancer-specific survival (CSS) analysis was ascertained. The CSS was defined as the time from surgery to cancer-related death. The optimal cut off levels for the LMR were by applying receiver operating curve (ROC) analysis. The association between the clinic pathological features and the LMR with CSS was analyzed by using Kaplan-Meier curves and compared by the log-rank test. The clinic pathological features was correlated with the LMR by $X^2$-test. The multivariate analysis was performed using the Cox proportional hazards
regression. Hazard ratios (HRs) estimated from the Cox-regression analysis were reported as relative risks with corresponding 95% confidence intervals. All statistical analyses were performed using the Statistical Package for Social Sciences version 19.0 (SPSS Inc, Chicago, IL, USA). A two-sides $P$ value of < 0.05 was considered statistically significant.

**Results**

In our study, 708 patients were enrolled. 4 patients were excluded because they died of postoperative complications. 71 patients were belong to pT1 stage. 62 patients were lost to follow-up. At last, 571 patients were included in this study. 113(19.8%) were women and 458(80.2%) were men, with an age range from 28 to 89 years. The median age at time of diagnosis was 61.9 years. The median follow-up time was 63.5 months (range 1 to 115). The basic clinic pathological characteristics of patients are presented in Table 1.
### Table 1
Association between clinicopathological parameters and LMR

| Parameter               | Overall | LMR > 3.64 | LMR ≤ 3.64 | P-value |
|-------------------------|---------|------------|------------|---------|
| n                       | 571(%)  | 388(%)     | 183(%)     |         |
| **Gender**              |         |            |            |         |
| Female                  | 113(19.8) | 87(22.4)   | 26(14.2)   | 0.021   |
| Male                    | 458(80.2) | 301(77.6)  | 157(85.8)  |         |
| **Age (years)**         |         |            |            |         |
| ≤ 65                    | 357(62.5) | 256(66.0)  | 98(53.6)   | 0.004   |
| >65                     | 217(37.5) | 132(34.0)  | 85(46.4)   |         |
| **Siwert type of AEG**  |         |            |            |         |
| II                      | 362(63.4) | 244(62.9)  | 118(64.5)  | 0.712   |
| III                     | 209(36.6) | 144(37.1)  | 65(35.5)   |         |
| **Tumor length (cm)**   |         |            |            |         |
| ≤ 3                     | 308(53.9) | 225(57.9)  | 83(45.4)   | 0.005   |
| >3                      | 263(46.1) | 163(42.1)  | 100(54.6)  |         |
| **Vessel invasion**     |         |            |            |         |
| Negative                | 461(80.7) | 319(82.2)  | 142(77.6)  | 0.191   |
| Positive                | 110(19.3) | 69(17.8)   | 41(22.4)   |         |
| **Nerve invasion**      |         |            |            |         |
| Negative                | 504(88.3) | 345(88.9)  | 159(86.9)  | 0.481   |
| Positive                | 67(11.7)  | 43(11.1)   | 24(13.1)   |         |
| **pT stage**            |         |            |            |         |
| 2                       | 60(10.5)  | 41(10.6)   | 19(10.4)   | 0.008   |
| 3                       | 108(18.9) | 88(22.7)   | 20(10.9)   |         |
| 4a                      | 271(47.5) | 172(44.3)  | 99(54.1)   |         |
| 4b                      | 132(23.1) | 87(22.4)   | 45(24.6)   |         |
| **pN stage**            |         |            |            |         |
| 0                       | 158(27.7) | 118(30.4)  | 40(21.9)   | 0.039   |
| 1                       | 36(6.3)   | 21(5.4)    | 15(8.2)    |         |
| Parameter          | Overall | LMR>3.64 | LMR ≤ 3.64 | P-value |
|-------------------|---------|----------|------------|---------|
| 2                 | 149(26.1) | 106(27.3) | 43(23.5) |         |
| 3                 | 228(39.9) | 143(36.9) | 85(46.4) |         |
| **pTNM stage**    |         |          |            |         |
| IB                | 37(6.5)  | 25(6.4)  | 12(6.6)   | 0.022   |
| IIA               | 55(9.6)  | 48(12.4) | 7(3.8)    |         |
| IIB               | 61(10.7) | 41(10.6) | 20(10.9)  |         |
| IIIA              | 65(11.4) | 48(12.4) | 17(9.3)   |         |
| IIIB              | 123(21.6)| 77(19.8) | 46(25.1)  |         |
| IIIC              | 230(40.2)| 149(38.4)| 81(44.3)  |         |
| **Adjuvant chemotherapy** |         |          |            |         |
| No                | 118(20.7) | 61(15.7) | 57(31.1)  | <0.001  |
| Yes               | 453(79.3)| 327(84.3)| 126(68.9) |         |

**Abbreviation:** LMR = lymphocyte to monocyte ratio.

Applying ROC curve analysis, the optimal cut-off levels for the LMR was 3.64 for CSS. The ROC curve was shown in Fig. 2. The area under the curve was 64.3% for CSS ($P<0.001$). Based on the optimum cut-off values of LMR, patients were divided into two groups for further analysis (Patients with a LMR ≤ 3.64 is the high-risk group and with a LMR>3.64 is the low-risk group). In our study cohort, clinic pathologic characters were compared between the ‘high-risk’ and ‘low-risk’ groups for LMR, we found significant associations between gender ($P=0.021$), age ($P=0.004$), tumor length ($P=0.005$), pT stage ($P=0.008$), pN stage ($P=0.039$), pTNM stage ($P=0.022$) and adjuvant chemotherapy ($P<0.001$). (Table 1) The preoperative absolute neutrophil/lymphocyte/monocyte counts were shown in Table 2. The lymphocyte count tended to decrease in ‘high-risk’ group, and the monocyte count tended to decrease in ‘low-risk’ group. Of the 571 type II/III advanced AEG patients, 291(50.9%) died within the follow-up period, 104(56.8%) out of 183 patients with a LMR ≤ 3.64 and 187(48.2%) out of 388 patients with a LMR>3.64, respectively. As shown in Table 3, clinic pathological characters for prediction of CSS were further investigated by univariate analysis with Cox regression model. In univariate analysis, tumor length ($P<0.001$), pT stage ($P<0.001$; Figure 3A), pN stage ($P<0.001$; Fig. 3B), vessel invasion ($P=0.027$), pTNM stage ($P<0.001$; Fig. 3C) and LMR ($P=0.008$; Fig. 3D) were significantly associated with 5-year CSS (Table 3). Then all of the 6 variables above were included in a multivariate Cox proportional hazards model to adjust the effects of covariates. In that model, we demonstrated that pT stage (HR: 2.213, 95%CI: 1.315–3.724, $P=0.003$), pTNM stage (HR: 2.449, 95%CI: 1.198–5.006, $P=0.014$) and LMR (HR: 1.642, 95%CI: 1.242–2.171, $P=0.027$) were independent prognostic factors in patients with advanced type II/III AEG (Table 3). To evaluate if Siewert type II/III advanced AEG patients benefit from adjuvant chemotherapy after radical surgery compared with surgery alone, Kaplan-Meier analysis and log-rank test.
were performed. The 5-year CSS of all patients in 'high-risk' group (LMR \( \leq \) 3.64) was 43.2% compared with 51.8% in 'low-risk' group (LMR>3.64) (HR: 2.311, 95%CI: 1.639–3.254, \( P = 0.008 \); Fig. 3D). In our cohort, 453(79.3%) out of 571 patients received the adjuvant chemotherapy after radical surgery. In 'low-risk' group (LMR>3.64), the 5-year CSS in patients with surgery and adjuvant chemotherapy was 58.2% compared with 37.2% in patients with surgery alone (HR: 0.435, 95%CI: 0.223–0.732, \( P < 0.001 \); Fig. 4A). According to the treatment regimen(surgery alone versus surgery and adjuvant chemotherapy), no significant difference in the 5-year CSS was identified in 'high-risk' group (LMR \( \leq \) 3.64) (HR: 1.121, 95%CI: 0.733–1.725, \( P = 0.605 \); Fig. 4B).

### Table 2
The preoperative absolute neutrophil/lymphocyte/monocyte counts

| Parameter            | Overall       | LMR>3.64     | LMR \( \leq \) 3.64 |
|----------------------|---------------|--------------|----------------------|
| Total leucocyte count(X10\(^9\)/L) | 5.9 ± 1.9;5.6(1.3–18.3) | 5.6 ± 1.7;5.5(1.3–18.3) | 6.1 ± 2.2;5.6(2.7–12.1) |
| Neutrophil count(X10\(^9\)/L)       | 3.8 ± 1.8;3.4(0.9–15.3) | 3.4 ± 1.3;3.3(0.9–10.3) | 4.2 ± 2.0;3.9(1.3–15.3) |
| Lymphocyte count (X10\(^9\)/L)      | 1.7 ± 0.5;1.5(0.5–4.1) | 1.9 ± 0.5;1.9(1.3–4.1) | 1.4 ± 0.4;1.3(0.5–3.7) |
| Monocyte count (X10\(^9\)/L)        | 0.4 ± 0.1;0.3(0.1–1.1) | 0.3 ± 0.1;0.3(0.1–0.9) | 0.4 ± 0.1;0.4(0.2–1.1) |
| Platelet count(X10\(^9\)/L)         | 189 ± 78;187(55–560) | 190 ± 74;186(60–463) | 191 ± 81;188(55–560) |
| Hemoglobin(g/L)                | 122 ± 22;126(70–156) | 124 ± 23;122(75–156) | 118 ± 20;118(70–146) |

Abbreviation: LMR = lymphocyte to monocyte ratio.
Table 3
Univariate and multivariate analysis of LMR for CSS in patients with type II/III of advanced AEG

| Parameter                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR(95%CI)           | P-value               | HR(95%CI)           | P-value   |
| **Gender**                 |                     |                       |                      |
| Female                     | 1(reference)        | 0.592                 |                       |
| Male                       | 1.082(0.811–1.443)  |                       |                       |
| **Age(years)**             |                     |                       |                      |
| ≤ 65                       | 1(reference)        | 0.227                 |                       |
| >65                        | 1.150(0.917–1.443)  |                       |                       |
| **Siewert type of AEG**    |                     |                       |                      |
| II                         | 1(reference)        | 0.288                 |                       |
| III                        | 0.882(0.699–1.112)  |                       |                       |
| **Tumor length(cm)**       |                     |                       |                      |
| ≤ 3                        | 1(reference)        | < 0.001               | 1(reference)         | 0.696     |
| >3                         | 3.753(2.299–6.127)  | 1.059(0.793–1.415)    |                       |
| **pT stage**               |                     |                       |                      |
| T2                         | 1(reference)        | < 0.001               | 1(reference)         | 0.003     |
| T3                         | 2.131(1.550–4.784)  | 2.213(1.315–3.724)    |                       |
| T4a                        | 4.179(2.102–8.307)  | T2 versus T3-4       |                       |
| T4b                        | 6.121(3.134–11.956) |                       |                       |
| **pN stage**               |                     |                       |                      |
| N0                         | 1(reference)        | < 0.001               | 1(reference)         | 0.214     |
| N1                         | 1.109(0.586–2.099)  | 0.862(0.683–1.089)    |                       |
| N2                         | 1.641(1.176–2.289)  | N0 versus N1-3       |                       |
| N3                         | 3.031(2.282–4.027)  |                       |                       |
| **pTNM stage**             |                     |                       |                      |
| I                          | 1(reference)        | < 0.001               | 1(reference)         | 0.014     |
| II                         | 2.987(1.698–5.254)  | 2.449(1.198–5.006)    |                       |
### Table 1

|                         | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
| III                     | 5.148 (3.100-8.549) | I versus II + III stage |
| **Vessel invasion**     |                     |                       |
| negative                | 1 (reference)       | < 0.001               |
| positive                | 1.872 (1.371-2.557) | 0.852 (0.674-1.077)   |
| **Nerve invasion**      |                     |                       |
| negative                | 1 (reference)       | 0.319                 |
| positive                | 1.156 (0.869-1.538) |                       |
| **LMR**                 |                     |                       |
| > 3.64                  | 1 (reference)       | 0.008                 |
| ≤ 3.64                  | 2.311 (1.639-3.254) | 1.642 (1.242-2.171)   |
| **Adjuvant chemotherapy**|                     |                       |
| Yes                     | 1 (reference)       | 0.351                 |
| No                      | 1.151 (0.857-1.541) |                       |

Abbreviations: CCS = cancer-specific survival; LMR = lymphocyte to monocyte ratio;

### Discussion

Recently, systemic inflammation has been found to correlate with tumor progression. Leucocytes in the tumor microenvironment promote tumor growth, angiogenesis and metastasis. Many peripheral inflammatory markers including PLR, NLR and LMR and their prediction of clinical outcomes in solid tumor entities have been uncovered. In this study, we examined a large cohort of patients with advanced type II AEG and investigated the prognostic significance of preoperative lymphocyte to monocyte ratio as a biomarker for predicting the outcomes after radical surgery.

As we all know, lymphocytes play an essential role in systemic inflammatory response to tumorous disease, including the inhibition of tumor cell proliferation and migration. Lymphocytes are the important components of the adaptive and innate immune system and the cellular basis of immunosurveillance. A decreased lymphocyte count is assumed to reflect an insufficient immunologic reaction to the tumor, thus promoting tumor cell apoptosis and metastasis. Some studies have shown a prognostic impact of tumor-infiltrating lymphocytes (TILs) in a series of cancers including gastric...
cancer\[17, 18\]. In the study of gastric adenocarcinoma, dense infiltration of CD3 + and CD8 + TILs had been associated with an optimistic prognosis\[17\]. In esophageal adenocarcinoma, the lower level of the FOXP3 + regulatory T cell (Treg) infiltrate present in the residual tumor or scar correlated with the more pathological response \[19\]. In recent study, Higher levels of TILs in the pathological specimen were associated with significant pathological response to neoadjuvant chemotherapy (NAC), increased levels of CD4 + and CD8 + TILs were associated with significant local tumor regression and lymph node downstaging\[20\].

The role of monocytes in tumor invasion, proliferation and metastasis is important. Monocytes can differentiate into tumor-associated macrophages (TAMs) in the tumor microenvironment. TAMs are recruited at the tumor site, where they accelerate tumor progression through the angiogenesis and anti-immune responses\[21\]. More and more evidence show that tumor-associated macrophages (TAMs) suppress the immune system of the host and promote tumor angiogenesis, proliferation and migration \[22\]. Macrophages are capable of producing osteonectin, which is essential in forming metastasis. This evidence suggests a tumorous potential of monocytes due to formation of different macrophage phenotypes that promote the malignant process. The high absolute monocytes count in the peripheral blood is reported to stand for the formation of TAMs and an elevated tumor burden in patients\[23\]. Therefore, it is not surprising that peripheral blood monocytosis is an adverse prognostic factor for various tumors. The LMR might be a good reflection of responsiveness of the immune system of the host and a microenvironment marker of tumor burden. The prognostic values of LMR in patients with AEG remain uncertain.

In our study, we set 3.64 as the cut-off levels for the LMR by applying ROC curve analysis, different from some other studies, such as 4.0 in the study by Hirahara N\[24\], 2.86 in pancreatic adenocarcinoma by Li’s study\[25\], a decreased peripheral lymphocyte to monocyte ratio (LMR) has been identified as a poorer prognostic indicator in various cancers\[26, 27\]. From Table 2, we found that the median of Lymphocyte count was higher in ‘LMR>3.64’(1.9) than in ‘LMR ≤ 3.64’(1.3). The median of monocyte count was nearly the same in two groups(0.3vs0.4). 5-year CSS with ‘LMR>3.64’ was 51.8% higher than 43.2% with ‘LMR ≤ 3.64’ (P = 0.008; Fig. 2D). Sometimes TAMs not only enhance tumor growth and progression, but also modulate the efficacy of various forms of anticancer therapy, such as chemotherapy and radiotherapy. In some circumstances, they also facilitate tumor regrowth, revascularization, and spread after the treatment\[28\]. In patients with esophageal cancer, infiltration with CD68 + and CD163 + TAMs, especially M2 macrophages, is associated with a poor prognosis for patients undergoing neoadjuvant chemotherapy\[29\]. Not only the first-line chemotherapeutic drug, but also epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had a poor response in patients with advanced non-small cell lung cancer\[30\]. As we all know, how to predict whether patients of AEG can benefit from chemotherapy was still a problem which perplexed physicians for many years. Our results suggest that ‘high-risk’ patients based on LMR ≤ 3.64 do not benefit from 5-fluorouracil-based adjuvant chemotherapy. For high-risk patients of AEG, we should avoid to use of adjuvant 5-fluorouracil-based chemotherapy.
until disease progression. Moreover, the LMR provides an easy available and low price biomarker with outcome.

To the best of our knowledge this is the first study to assess the LMR in advanced type II/III AEG. The strength of this study is the large sample size and the long follow-up period. However, there are some possible limitations associated with this study. Firstly, because of the retrospective design of the study, we cannot fully exclude the selection bias in our cohort. Furthermore, potential confounding factors such as infection, coronary syndrome, and diabete mellitus, that might affect the lymphocyte and monocyte count were not taken into consideration. Finally, although we set 3.64 as the cut-off level by using ROC curve, different cut-off levels may also valuable. So large prospective and multi-centric clinical trials should be performed to confirm our findings in future.

Declarations

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (NO: 81602425) and the Natural Science Foundation of Anhui Province (NO: 1508085QH152). The funders had no role in study design, data collection and analysis, manuscript preparation, or submission for publication. All those named as authors have made a sufficient contribution to the final manuscript for submission. All authors declare no conflict of interest, and agree on consent to be listed as coauthors.

Author’s contributions

Jiawei Zhang contributed to study concept and design, data acquisition, analysis and interpretation, statistical analysis, and manuscript writing; Ke Chen,Bo Chen, Maoming Xiong and Aman Xu involved in data acquisition and manuscript critical revision. All the authors reviewed and approved the final manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that there is no conflict of interests.

Ethics standards

This research was permitted by the Ethical Committee of the First Affiliated Hospital of An Hui Medical University. Written informed consent was obtained from each patient. The study complied with current Chinese law and was performed in accordance with the principles of Declaration of Helsinki(1964).

References
1. Oda I, Abe S, Kusano C, et al. Correlation between endoscopic macroscopic type and invasion depth for early esophagogastric junction adenocarcinomas. Gastric Cancer. 2011;14:22–7.

2. Saito H, Fukumoto Y, Osaki T, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30:1864–9.

3. Siewert JR, Stein HJ. Classification of adenocarcinoma of the esophagogastric junction. Br J Surg. 1998;85:1457–9.

4. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am. 2006;15:751–64.

5. Kofoed SC, Muhic A, Baeksgaard L, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg. 2012;101:26–31.

6. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.

7. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–68.

8. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29:17–24.

9. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60 – 00 trial. J Clin Oncol. 2010;28:466–74.

10. Liu JS, Huang Y, Yang X, Feng JF. A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma. Am J Cancer Res. 2015;5:2180–9.

11. Jiang N, Deng JY, Liu Y, Ke B, Liu HG, Liang H. The role of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer. Biomarkers. 2014;19:444–51.

12. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004;90:2053–8.

13. Absenger G, Szkandera J, Pichler M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer. 2013;109:395–400.

14. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23:265–73.

15. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–14 e2105.
16. Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435–40.

17. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99:1704–11.

18. Chung YR, Kim HJ, Jang MH, Park SY. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat. 2017;161(3):409–20.

19. Vacchelli E, Semeraro M, Enot DP, et al. Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget. 2015;6:20840–50.

20. Noble F, Mellows T, McCormick Matthews LH, et al. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother. 2016;65:651–62.

21. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875–85.

22. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–6.

23. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.

24. Hirahara N, Fujii Y, Yamamoto T, et al. Validation of a novel prognostic scoring system using inflammatory response biomarkers in patients undergoing curative thoracoscopic esophagectomy for esophageal squamous cell carcinoma. Onco Targets Ther. 2017;10:363–70.

25. Li GJ, Xu HW, Ji JJ, Yang F, Gao BQ. Prognostic value of preoperative lymphocyte-to-monocyte ratio in pancreatic adenocarcinoma. Onco Targets Ther. 2016;9:1085–92.

26. Neofytou K, Smyth EC, Giakoustidis A, et al. The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting. Ann Surg Oncol. 2015;22:4353–62.

27. Szkandera J, Gerger A, Liegl-Atzwanger B, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135:362–70.

28. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277–86.

29. Sugimura K, Miyata H, Tanaka K, et al. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol. 2015;111:752–9.

30. Chung FT, Lee KY, Wang CW, et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer. 2012;131:E227–35.